title: The role of apheresis therapy for ABO incompatible living donor liver transplantation: the Kyoto University experience.
abstract: Liver transplantation is a radical surgical therapy for end-stage liver disease. Although in Japan organ transplantation from brain-dead donors (BDD) has been allowed since October 1997, to date, only 29 liver grafts from BDD have been obtained. Thus, most of the liver transplantations carried out use living-donor liver transplantation (LDLT), and BDD liver transplantation is only used in rare cases. In order to carry out LDLT more safely, apheresis (plasmapheresis: PE) plays a major role in our country because of the prevalence of LDLT wherein later re-transplantation is difficult. Thus, because of a limited donor supply and because the needs of patients with end-stage liver disease is critical, use of grafts from ABO-incompatible (ABO-I) donors might be the only available option. From June 1990 to November 2005, 1100 patients underwent 1151 LDLT cases at Kyoto University Hospital. Additionally, 159 LDLT cases (13.8%) received ABO-I living-donor liver grafts. The role of apheresis in ABO-I LDLT is the reduction of antibody titers such as anti-A or anti-B antibody. We carry out preoperative PE as a general rule for ABO-I cases, and the recipient's antibody level against the donor's blood type is decreased to one eighth of the baseline value before LDLT. Until now, baseline immunosuppressive agents included steroids, tacrolimus and cyclophosphamide. At first, splenectomy was carried out during surgery to suppress antibody production, and intraportal (PV) infusion therapy was carried out to control local disseminated intravascular coagulation (DIC) occurring in ABO-I grafts. At that time, three drugs-methylprednisolone, prostaglandin E1 (PGE1), and gabexate mesylate (FOY) were infused continuously for 3 weeks after LDLT. At present, instead of PV infusion therapy, hepatic artery infusion therapy without splenectomy is adopted because of portal thrombosis, and two drugs- methylprednisolone and PGE1- are infused continuously for 3 weeks following LDLT. Recently, we introduced anti-CD20 monoclonal antibody (Rituximab) instead of splenectomy for B cell deletion before ABO-I LDLT. In the present article, we describe the role of apheresis around ABO-I LDLT based on our recent experiences.
authors.affiliation: Department of Transplantation Immunology, Faculty of Medicine, Kyoto University, Kyoto City, Kyoto, Japan. kkozaki@kuhp.kyoto-u.ac.jp
authors.forename: Koichi
authors.initials: K
authors.lastname: Kozaki
authors.forename: Hiroto
authors.initials: H
authors.lastname: Egawa
authors.forename: Mikiko
authors.initials: M
authors.lastname: Ueda
authors.forename: Fumitaka
authors.initials: F
authors.lastname: Oike
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yoshizawa
authors.forename: Atsushi
authors.initials: A
authors.lastname: Fukatsu
authors.forename: Yasutsugu
authors.initials: Y
authors.lastname: Takada
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D001781:Blood Component Removal; D006084:Graft Rejection / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008099:Liver / Q000473:pathology; D016031:Liver Transplantation / Q000276:immunology; D019520:Living Donors; D009336:Necrosis; D010956:Plasmapheresis; D000069283:Rituximab; D013156:Splenectomy
chemical_list: D000017:ABO Blood-Group System; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069283:Rituximab